Positive News Sentiment NASDAQ:INKT MiNK Therapeutics - INKT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.29 0.00 (0.00%) (As of 01/31/2023 05:19 PM ET) Add Compare Share Share Today's Range$2.21▼$2.2950-Day Range$2.13▼$2.6552-Week Range$1.09▼$4.32Volume25,948 shsAverage Volume11,192 shsMarket Capitalization$77.38 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MiNK Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside205.7% Upside$7.00 Price TargetShort InterestHealthy1.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.84) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector328th out of 1,055 stocksBiological Products, Except Diagnostic Industry57th out of 170 stocks 3.5 Analyst's Opinion Consensus RatingMiNK Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, MiNK Therapeutics has a forecasted upside of 205.7% from its current price of $2.29.Amount of Analyst CoverageMiNK Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.73% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiNK Therapeutics has recently decreased by 15.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMiNK Therapeutics does not currently pay a dividend.Dividend GrowthMiNK Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INKT. Previous Next 4.4 News and Social Media Coverage News SentimentMiNK Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MiNK Therapeutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for INKT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.21% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.41% of the stock of MiNK Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MiNK Therapeutics are expected to decrease in the coming year, from ($0.84) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiNK Therapeutics is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiNK Therapeutics is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMiNK Therapeutics has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MiNK Therapeutics (NASDAQ:INKT) StockMiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Read More Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address INKT Stock News HeadlinesJanuary 11, 2023 | finance.yahoo.comMiNK Therapeutics to Participate in B. Riley Securities Oncology ConferenceDecember 22, 2022 | finance.yahoo.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call TranscriptJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 17, 2022 | finance.yahoo.comMiNK Therapeutics to Participate in Evercore ISI HealthCONx ConferenceNovember 11, 2022 | msn.comMassachusetts company MiNK Therapeutics working to make chemotherapy a thing of the pastNovember 10, 2022 | finance.yahoo.comMiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy PipelineNovember 6, 2022 | finance.yahoo.comWill MiNK Therapeutics (NASDAQ:INKT) Spend Its Cash Wisely?November 3, 2022 | finance.yahoo.comMiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial ResultsJanuary 31, 2023 | PressReach (Ad)Top Lithium StockToday's stock market report features a battery metal lithium stock with great potential.October 20, 2022 | finance.yahoo.comMiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business UpdateOctober 7, 2022 | benzinga.comMiNK Selected for Five Presentations at Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingOctober 5, 2022 | finance.yahoo.comMiNK Therapeutics to Host R&D Event November 10, 2022September 10, 2022 | seekingalpha.comINKT MiNK Therapeutics, Inc.August 31, 2022 | finance.yahoo.comMiNK Therapeutics to Participate at Upcoming Investor ConferencesAugust 16, 2022 | finance.yahoo.comDo Insiders Own Lots Of Shares In MiNK Therapeutics, Inc. (NASDAQ:INKT)?August 9, 2022 | proactiveinvestors.comMiNK Therapeutics pioneering iNKT cell therapies to treat cancer and other immune-mediated diseasesAugust 9, 2022 | finance.yahoo.comMiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial ResultsAugust 2, 2022 | finance.yahoo.comMiNK Therapeutics to Participate at BTIG Biotechnology ConferenceJuly 27, 2022 | finance.yahoo.comMiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business UpdateJune 18, 2022 | seekingalpha.comELMS, EMWP and EOSE among mid-day moversMay 25, 2022 | finance.yahoo.comMiNK Therapeutics Announces Virtual Annual Shareholders MeetingMay 10, 2022 | finance.yahoo.comMiNK Therapeutics Corporate Update and First Quarter 2022 Financial ReportMay 9, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn SituationApril 27, 2022 | finance.yahoo.comMiNK Therapeutics to Report First Quarter 2022 Financial Results and Business UpdateApril 9, 2022 | seekingalpha.comCAN, LILM and AUR among mid-day moversMarch 18, 2022 | seekingalpha.comMiNK Therapeutics GAAP EPS of -$0.18 beats by $0.23March 18, 2022 | finance.yahoo.comMiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address INKT Company Calendar Last Earnings11/03/2022Today1/31/2023Next Earnings (Estimated)3/17/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INKT CUSIPN/A CIK1840229 Webwww.minktherapeutics.com Phone212-994-8250FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+205.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-168.94% Return on Assets-78.30% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book3.23Miscellaneous Outstanding Shares33,790,000Free Float29,323,000Market Cap$77.38 million OptionableNot Optionable Beta-0.65 Key ExecutivesDr. Garo H. Armen Ph.D. (Age 69)Exec. Chairman Dr. Jennifer S. Buell Ph.D. (Age 47)Pres, CEO & Director Comp: $232.54kDr. Marcus Antonius van Dijk Ph.D. (Age 60)Chief Scientific Officer Ms. Christine M. Klaskin (Age 56)Treasurer Comp: $20.02kMr. Patrick N. Jordan M.B.A.VP of Bus. OperationsMs. Kimberly HaHead of Investor RelationsMs. Heather BoussiosGen. Counsel & Chief Compliance OfficerJoy Zhou Ph.D.VP & Head of CMCMore ExecutivesKey CompetitorsaTyr PharmaNASDAQ:LIFECurisNASDAQ:CRISOrchard TherapeuticsNASDAQ:ORTXX4 PharmaceuticalsNASDAQ:XFORJasper TherapeuticsNASDAQ:JSPRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 49,107 shares on 11/15/2022Ownership: 0.145%First Republic Investment Management Inc.Bought 81,500 shares on 11/4/2022Ownership: 0.243%Ulf WiinbergBought 3,339 shares on 7/18/2022Total: $4,440.87 ($1.33/share)View All Insider TransactionsView All Institutional Transactions INKT Stock - Frequently Asked Questions Should I buy or sell MiNK Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INKT shares. View INKT analyst ratings or view top-rated stocks. What is MiNK Therapeutics' stock price forecast for 2023? 1 Wall Street analysts have issued twelve-month price targets for MiNK Therapeutics' stock. Their INKT share price forecasts range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 205.7% from the stock's current price. View analysts price targets for INKT or view top-rated stocks among Wall Street analysts. How have INKT shares performed in 2023? MiNK Therapeutics' stock was trading at $2.61 on January 1st, 2023. Since then, INKT shares have decreased by 12.3% and is now trading at $2.29. View the best growth stocks for 2023 here. When is MiNK Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 17th 2023. View our INKT earnings forecast. How were MiNK Therapeutics' earnings last quarter? MiNK Therapeutics, Inc. (NASDAQ:INKT) released its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. When did MiNK Therapeutics IPO? (INKT) raised $43 million in an initial public offering (IPO) on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share. What is MiNK Therapeutics' stock symbol? MiNK Therapeutics trades on the NASDAQ under the ticker symbol "INKT." How do I buy shares of MiNK Therapeutics? Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MiNK Therapeutics' stock price today? One share of INKT stock can currently be purchased for approximately $2.29. How much money does MiNK Therapeutics make? MiNK Therapeutics (NASDAQ:INKT) has a market capitalization of $77.38 million. The company earns $-30,210,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. How can I contact MiNK Therapeutics? The official website for the company is www.minktherapeutics.com. The company can be reached via phone at 212-994-8250 or via email at investor@minktherapeutics.com. This page (NASDAQ:INKT) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.